Aladdin®Peptide ligands
Aladdin®Peptide ligands
Product Manager：Harrison Michael
Introduction
Peptide ligands are a class of important molecules formed by the connection of amino acids through peptide bonds, extensively present in living organisms, and involved in a variety of physiological and biochemical processes. They occupy an important position in life sciences research due to their unique structure and function, especially playing a key role in signal transduction, receptor regulation, enzyme activity modulation, and immune responses. In addition, peptide ligands also show broad application prospects in drug development and biotechnology fields due to their high specificity and biocompatibility.
The study of peptide ligands covers multiple scientific fields. In basic research, they are used to elucidate molecular mechanisms of action and the complex regulation of biological networks; in application development, peptide ligands are widely applied in the design of targeted therapeutic drugs, the development of vaccines, and the improvement of disease diagnostic tools. Especially in the research of tumors, neurological diseases, and infectious diseases, peptide ligands provide new therapeutic targets and diagnostic strategies. Through the study of peptide ligands, scientists can gain a deeper understanding of the dynamic regulation of life systems and develop more clinically potential solutions.
Aladdin Scientific offers a rich selection of peptide ligand products, which, with their excellent purity and stability, help researchers achieve breakthroughs in the screening, synthesis, functional research, and application development of peptide ligands. From basic biological research to cutting-edge technology exploration, Aladdin Scientific is always committed to providing comprehensive support for your scientific discoveries and innovative practices, making it a trustworthy partner on your research journey.
Agonist
Cat.No | Product Name | CAS | Size |
Human angiotension Ⅱ Relative Molecular Weight (AT1,AT2 receptor full agonist) | 4474-91-3 | 5mg | |
[Arg8]-Vasotocin (OT receptor full agonist) | 113-80-4 | 1mg;2mg;5mg;25mg | |
[Arg8]-Vasotocin (V1A, V1B, V2 receptor full agonist) | 113-80-4 | 1mg;2mg;5mg;25mg | |
Apelin 36 (human) (apelin receptor full agonist) | 252642-12-9 | 1mg;5mg;25mg | |
Apelin 17 (apelin receptor agonist) | 217082-57-0 | 1mg;5mg;25mg;50mg | |
Amylin, amide, rat acetate (AMY1,AMY2,AMY3 receptor full agonist) | 124447-81-0 | 500μg;1mg;5mg | |
Amylin, amide, rat acetate (CT receptor full agonist) | 124447-81-0 | 500μg;1mg;5mg | |
Angiotensin 1-7 (AT2 receptor agonist) | 51833-78-4 | 100mg;5mg;25mg | |
Angiotensin 1-7 (MAS1 agonist) | 51833-78-4 | 100mg;5mg;25mg | |
Bombesin acetate salt hydrate (BB1,BB2 receptor full agonist) | 31362-50-2 | 1mg;5mg;25mg;100mg | |
Bombesin acetate salt hydrate (BB2 receptor agonist) | 31362-50-2 | 1mg;5mg;25mg;100mg | |
Bradykinin Fragment 1-8 acetate salt hydrate(B1,B2 receptor full agonist) | 15958-92-6 | 10mg;5mg;25mg | |
BIM 23052 (SST1, SST2, SST3, SST4, SST5 receptor full agonist) | 133073-82-2 | 1mg | |
BIM 23056 (SST2, SST3, SST5 receptor full agonist) | 150155-61-6 | 1mg;5mg;25mg | |
BAM (8-22) (Bovine Adrenal Medulla 8-22) (MRGPRX1 full agonist) | 412961-36-5 | 1mg | |
Bradykinin (B1,B2 receptor full agonist) | 58-82-2 | 10mg;50mg;250mg | |
Calcitonin Gene Related Peptide rat (ACKR3 agonist) | 96827-03-1 | 0.5mg;1mg;2.5mg | |
Calcitonin Gene Related Peptide rat (AM1,AM2 receptor full agonist) | 96827-03-1 | 0.5mg;1mg;2.5mg | |
Calcitonin Gene Related Peptide rat (CGRP receptor full agonist) | 96827-03-1 | 0.5mg;1mg;2.5mg | |
CCK Octapeptide sulfated (CCK1,CCK2 receptor full agonist) | 25126-32-3 | 1mg;5mg;10mg;25mg | |
Chemerin-9, Human (chemerin receptor 1 full agonist) | 676367-27-4 | 1mg | |
Chemerin-9, Human (chemerin receptor 2 agonist) | 676367-27-4 | 1mg | |
C5a desArg Anaphylatoxin (Not Recombinant) (C5a1,C5a2 receptor full agonist) | 80295-54-1 | 50μg | |
D118757 | Diabetes Associated Peptide Amide human (AMY1, AMY2, AMY3 receptor full agonist) | 122384-88-7 | 1mg;5mg |
D118757 | Diabetes Associated Peptide Amide human (CT receptor full agonist) | 122384-88-7 | 1mg;5mg |
D123296 | Desmopressin Acetate (OT receptor full agonist) | 16679-58-6 | 1mg;5mg;25mg;100mg |
D123296 | Desmopressin Acetate (V1A,V2 receptor full agonist) | 16679-58-6 | 1mg;5mg;25mg;100mg |
D123296 | Desmopressin Acetate (V1B receptor partial agonist) | 16679-58-6 | 1mg;5mg;25mg;100mg |
D275239 | [D-Ala2]-Deltorphin II (Delta Receptor full agonist) | 122752-16-3 | 1mg |
D275414 | DAMGO (KOR partial agonist) | 78123-71-4 | 1mg;5mg;25mg;50mg |
D275414 | DAMGO (MOR full agonist) | 78123-71-4 | 1mg;5mg;25mg;50mg |
D275681 | [D-Trp6]-LH-RH (GnRH1 receptor full agonist) | 57773-63-4 | 10mg;25mg; |
E107854 | Exendin-4 (GLP-1 receptor agonist) | 141758-74-9 | 0.5mg;1mg;5mg;2.5mg |
E107854 | Exendin-4 (GLP-1 receptor full agonist) | 141758-74-9 | 0.5mg;1mg;5mg;2.5mg |
E118808 | Endomorphin 1 (Delta Receptor full agonist) | 189388-22-5 | 5mg;10mg;25mg;100mg |
E118808 | Endomorphin 1 (MOR full agonist) | 189388-22-5 | 5mg;10mg;25mg;100mg |
E118809 | Endomorphin-2 (MOR full agonist) | 141801-26-5 | 5mg;10mg;25mg; |
E118811 | Endothelin 3 human, rat (ETB receptor full agonist) | 117399-93-6 | 500μg;1mg;2.5mg; |
E118899 | β-Endorphin, human (Delta Receptor full agonist) | 61214-51-5 | 0.5mg;1mg;5mg |
E118899 | β-Endorphin, human (KOR,MOR full agonist) | 61214-51-5 | 0.5mg;1mg;5mg |
E287473 | Eledoisin (NK1,NK3 receptor full agonist) | 69-25-0 | 1mg;5mg;10mg; |
G118937 | Galanin, human (GAL1,GAL2,GAL3 receptor full agonist) | 119418-04-1 | 1mg;5mg |
G118955 | Gastric Inhibitory Polypeptide human (GIP receptor full agonist) | 100040-31-1 | 0.5mg;1mg;2.5mg;10mg |
G118956 | Gastrin Ⅰ, human (CCK1,CCK2 receptor full agonist) | 10047-33-3 | 1mg;5mg;25mg |
Gastrin Ⅰ, human (CCK2 receptor agonist) | 10047-33-3 | 1mg;5mg;25mg | |
Growth Hormone Releasing Factor human (GHRH receptor agonist) | 83930-13-6 | 1mg;5mg | |
Growth Hormone Releasing Factor human (VPAC1 receptor agonist) | 83930-13-6 | 1mg;5mg | |
Glucagon (GLP-1 receptor full agonist) | 9007-92-5 | 1mg;5mg | |
Glucagon (glucagon receptor full agonist) | 9007-92-5 | 1mg;5mg | |
Glucagon-Like Peptide II (rat) (GLP-2 receptor full agonist) | 195262-56-7 | 500μg;1mg;2.5mg | |
Ghrelin (human) (ghrelin receptor full agonist) | 258279-04-8 | 1mg;5mg | |
GLP-1 (7-37) (GLP-1 receptor full agonist) | 106612-94-6 | 1mg;5mg;10mg;25mg | |
GR 64349 (NK2 receptor full agonist) | 137593-52-3 | 1mg | |
GLP-2 (human) (GLP-2 receptor full agonist) | 223460-79-5 | 1mg;5mg;10mg; | |
Glucagon-like peptide 1 (7-36) amide (human, rat)(GLP-1 receptor full agonist) | 107444-51-9 | 5mg;10mg; | |
GHRP-2 (ghrelin receptor full agonist) | 158861-67-7 | 5mg;25mg;100mg;500mg | |
Hexarelin Acetate (ghrelin receptor full agonist) | 140703-51-1 | 5mg;10mg;25mg;50mg | |
JMV 449 (NTS1 receptor full agonist) | 139026-66-7 | 1mg | |
Kisspeptin-13 (4-13) (human) (KiSS-1 (112-121)(kisspeptin receptor full agonist) | 374675-21-5 | 1mg | |
Kassinin (NK1,NK3 receptor full agonist) | 63968-82-1 | 1mg;5mg | |
Litorin (BB1,BB2 receptor full agonist) | 55749-97-8 | 1mg;2mg;5mg | |
Lanreotide (SST2, SST3, SST5 receptor full agonist) | 108736-35-2 | 1mg;5mg;25mg;100mg | |
Liraglutide (GLP-1 receptor full agonist) | 204656-20-2 | 1mg;5mg;25mg;100mg | |
Lys-[Des-Arg9]Bradykinin (B1 receptor full agonist) | 71800-36-7 | 1mg | |
Lys-[Des-Arg9]Bradykinin (B2 receptor partial agonist) | 71800-36-7 | 1mg | |
[Leu5]-Enkephalin (Delta Receptor full agonist) | 58822-25-6 | 10mg;25mg;100mg | |
[Leu5]-Enkephalin (KOR full agonist) | 58822-25-6 | 10mg;25mg;100mg | |
[Leu5]-Enkephalin (MOR partial agonist) | 58822-25-6 | 10mg;25mg;100mg | |
[Leu¹³]-Motilin porcine (motilin receptor full agonist) | 116283-54-6 | 1mg | |
MMK1 TFA (FPR2/ALX full agonist) | 271246-66-3 | 1mg;5mg;10mg;25mg | |
γ1-MSH TFA (MC3 receptor full agonist) | 72629-65-3 | 1mg;5mg;10mg; | |
Metastin (human) (kisspeptin receptor full agonist) | 374683-24-6 | 100μg | |
[Nle4, D-Phe7]-α-Melanocyte Stimulating Hormone trifluoroacetate salt (MC1, MC3, MC4, MC5 receptor full agonist) | 75921-69-6 | 1mg;5mg;25mg;100mg | |
Neurotensin (NTS1,NTS2 receptor full agonist) | 55508-42-4 | 1mg;5mg;10mg;25mg; | |
Nociceptin(Orphanin FQ) (ORL1 agonist, NOP receptor full agonist) | 170713-75-4 | 1mg;5mg | |
Neurokinin A (NK1,NK2,NK3 receptor full agonist) | 86933-74-6 | 5mg | |
Neuropeptide Y (NPY) (human,rat) (Y1,Y2,Y4,Y5 receptor full agonist) | 90880-35-6 | 500μg;1mg;5mg; | |
Neuromedin U-25 (human) (NMU) (NMU1,NMU2 receptor full agonist) | 312306-89-1 | 500μg | |
Neuropeptide Y (porcine) (Y1,Y2,Y4 receptor full agonist) | 83589-17-7 | 200μg | |
Neurokinin B (human, porcine) (NK1,NK2,NK3 receptor full agonist) | 86933-75-7 | 1mg;5mg;25mg | |
Neuropeptide S (human) (NPS receptor full agonist) | 412938-67-1 | 1mg;5mg;10mg | |
Neuromedin N (rat, mouse, porcine, canine) (NTS1,NTS2 receptor full agonist) | 92169-45-4 | 1mg;2mg;5mg | |
Nickel(II) cyanide tetrahydrate (XCR1 agonist) | 13477-95-7 | 10g | |
N-Formyl-Met-Leu-Phe (FPR1 full agonist) | 59880-97-6 | 10mg | |
N-Formyl-Met-Leu-Phe (FPR2/ALX full agonist) | 59880-97-6 | 10mg | |
Orexin A (bovine, human, mouse, rat) (OX1,OX2 receptor full agonist) | 205640-90-0 | 100μg;500μg;1mg | |
Pentagastrin (CCK1,CCK2 receptor full agonist) | 5534-95-2 | 25mg;100mg | |
Peptide YY human (Y1,Y2 receptor agonist) | 118997-30-1 | 1mg;2mg;5mg; | |
Peptide YY human (Y4 receptor full agonist) | 118997-30-1 | 1mg;2mg;5mg; | |
Peptide YY Fragment 3-36 human (Y1,Y2,Y4,Y5 receptor full agonist) | 126339-09-1 | 0.5mg;1mg;5mg | |
PACAP (1-27) (human) (PAC1,VPAC1,VPAC2 receptor agonist) | 127317-03-7 | 500μg;1mg;2.5mg; | |
[Pyr1]-Apelin 13 (apelin receptor full agonist) | 217082-60-5 | 1mg;5mg;10mg;50mg | |
PAMP-12 (human, porcine) (MRGPRX2 full agonist) | 196305-05-2 | 5mg;10mg; 25mg;50mg;100mg | |
[D-Ala²]Leucine enkephalin (Delta Receptor full agonist) | 64963-01-5 | 5mg;25mg;100mg;1g;5g | |
[D-Ala²]Leucine enkephalin (MOR full agonist) | 64963-01-5 | 5mg;25mg;100mg;1g;5g | |
Phyllomedusin (NK1 receptor full agonist) | 26145-48-2 | 1mg | |
Protirelin (TRH1,TRH2 receptor full agonist) | 24305-27-9 | 10mg;50mg;100mg | |
Ranatensin (BB1,BB2 receptor full agonist) | 29451-71-6 | 1mg;5mg;25mg | |
Sar-[D-Phe8]-des-Arg9-Bradykinin (B1 receptor full agonist) | 126959-88-4 | 1mg;5mg;10mg; | |
Somatostatin 1-28 (MRGPRX2 agonist) | 74315-46-1 | 500μg;1mg;2mg;5mg | |
Somatostatin 1-28 (SST1,SST2,SST3,SST4,SST5 receptor full agonist) | 74315-46-1 | 500μg;1mg;2mg;5mg | |
Senktide (NK3 receptor full agonist) | 106128-89-6 | 1mg;10mg;5mg;500μg | |
Substance P,Neurokinin P,Arg-Pro- Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu- Met-NH2,RPKPQQFFGLM-NH2 (MRGPRX2 agonist) | 33507-63-0 | 5mg;10mg;25mg;100mg | |
Substance P,Neurokinin P,Arg-Pro- Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu- Met-NH2,RPKPQQFFGLM-NH2 (MRGPRX2 agonist) | 33507-63-0 | 5mg;10mg;25mg;100mg | |
Semaglutide (GLP-1 receptor agonist) | 910463-68-2 | 1mg;5mg;25mg;100mg | |
Tirzepatide (LY3298176) (GIP receptor agonist) | 2023788-19-2 | 1mg;5mg | |
Tirzepatide (LY3298176) (GLP-1 receptor agonist) | 2023788-19-2 | 1mg;5mg | |
Urocortin human (CRF1,CRF2 receptor full agonist) | 176591-49-4 | 0.5mg;1mg;5mg | |
Urofollitropin (FSH receptor agonist) | 97048-13-0 | 1KU;5KU | |
Xenin 25 acetate salt (NTS2 receptor full agonist) | 144092-28-4 | 1mg;5mg |
Antagonist
Cat.No | Product Name | CAS | Size |
AP 811 (Binding agent of natriuretic peptide receptor 3) | 124833-45-0 | 1mg | |
BIM 23056 (SST5 receptor antagonist) | 150155-61-6 | 1mg;5mg;25mg | |
CTAP (Delta Receptor antagonist) | 103429-32-9 | 1mg;5mg;25mg | |
CTAP (MOR antagonist) | 103429-32-9 | 1mg;5mg;25mg | |
CTOP TFA | 103429-31-8 | 1mg;5mg;25mg; | |
Conantokin G (GluN2A,GluN2B,GluN2C,GluN2D antagonist) | 93438-65-4 | 500μg | |
α-Conotoxin GI (nicotinic acetylcholine receptor α1 subunit antagonist) | 76862-65-2 | 25mg | |
Exendin Fragment 9-39 (GLP-1 receptor antagonist) | 133514-43-9 | 0.5mg;1mg;5mg | |
IRL-2500 (ETB receptor antagonist) | 169545-27-1 | 1mg;5mg;10mg; | |
ICI 174,864 (Delta Receptor inverse agonist) | 89352-67-0 | 1mg;5mg | |
Neuropeptide Y (NPY) (human, rat) (PrRP receptor antagonist) | 90880-35-6 | 500μg;1mg;5mg; | |
Urantide (UT receptor antagonist) | 669089-53-6 | 1mg |
Channel Blocker
Cat.No | Product Name | CAS | Size |
Human angiotension Ⅱ Relative Molecular Weight (Related agents of K2P3.1) | 4474-91-3 | 5mg | |
Iberiotoxin (Related agents of KCa1.1) | 129203-60-7 | 1mg;100μg | |
Kaliotoxin (Related agents of Kv1.1,Kv1.3) | 145199-73-1 | 10μg | |
Margatoxin (Kv1.1,Kv1.2 inhibitor) | 145808-47-5 | 100μg | |
Margatoxin (Related agents of Kv1.3,Kv1.7) | 145808-47-5 | 100μg |
Gating Inhibitor
Cat.No | Product Name | CAS | Size |
Jingzhaotoxin III (Electrically dependent inhibition of Nav1.5) | 925463-91-8 | 100μg | |
Jingzhaotoxin III (Related agents of Kv2.1) | 925463-91-8 | 100μg |
Inhibitor
Cat.No | Product Name | CAS | Size |
Aprotinin from bovine lung (The combination of plasminogen) | 9087-70-1 | 5mg;25mg;50mg; | |
BIO 1211, α4β1(VLA-4)inhibitor (integrin α4β1 inhibitor) | 187735-94-0 | 1mg;5mg;10mg; | |
Calpeptin (calpain 1 inhibitor) | 117591-20-5 | 5mg;10mg;25mg; | |
Calpeptin (cathepsin K inhibitor) | 117591-20-5 | 5mg;10mg;25mg; | |
Calpeptin (CoV 3C-like (main) protease inhibitor) | 117591-20-5 | 5mg;10mg;25mg; | |
Compstatin,ICVVQDWGHHRCT | 206645-99-0 | 1mg;5mg;25mg;100mg | |
MLCK inhibitor peptide 18 (myosin light chain kinase inhibitor) | 224579-74-2 | 1mg | |
Opiorphin (Aminopeptidase N inhibitor) | 864084-88-8 | 1mg |
Aladdin：https://www.aladdinsci.com/